A practical reference on freeze-thaw: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-26 and is reviewed periodically as new material appears.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
=== Antidotes === Andexxa (Andexanet alfa) from Portola Pharmaceuticals is a recombinant protein that is given intravenously. It works as an antidote to all direct and indirect FXa inhibitors. Andexxa acts as a decoy receptor for Xa inhibitors.
== Peptides and proteins == A number of algorithms for estimating isoelectric points of peptides and proteins have been developed. Most of them use Henderson–Hasselbalch equation with different pK values. For instance, within the model proposed by Bjellqvist and co-workers, the pKs were determined between closely related immobilines by focusing the same sample in overlapping pH gradients. Some improvements in the methodology (especially in the determination of the pK values for modified amino acids) have been also proposed. More advanced methods take into account the effect of adjacent amino acids ±3 residues away from a charged aspartic or glutamic acid, the effects on free C terminus, as well as they apply a correction term to the corresponding pK values using genetic algorithm. Other recent approaches are based on a support vector machine algorithm and pKa optimization against experimentally known protein/peptide isoelectric points. Moreover, experimentally measured isoelectric point of proteins were aggregated into the databases. Recently, a database of isoelectric points for all proteins predicted using most of the available methods had been also developed. In practice, a protein with an excess of basic aminoacids (arginine, lysine and/or histidine) will bear an isoelectric point roughly greater than 7 (basic), while a protein with an excess of acidic aminoacids (aspartic acid and/or glutamic acid) will often have an isoelectric point lower than 7 (acidic).
=== Foundation === Wnt signaling begins when a Wnt protein binds to the N-terminal extra-cellular cysteine-rich domain of a Frizzled (Fz) family receptor. These receptors span the plasma membrane seven times and constitute a distinct family of G-protein coupled receptors (GPCRs). However, to facilitate Wnt signaling, co-receptors may be required alongside the interaction between the Wnt protein and Fz receptor. Examples include lipoprotein receptor-related protein (LRP)-5/6, receptor tyrosine kinase (RTK), and ROR2. Upon activation of the receptor, a signal is sent to the phosphoprotein Dishevelled (Dsh), which is located in the cytoplasm. This signal is transmitted via a direct interaction between Fz and Dsh. Dsh proteins are present in all organisms and they all share the following highly conserved protein domains: an amino-terminal DIX domain, a central PDZ domain, and a carboxy-terminal DEP domain. These different domains are important because after Dsh, the Wnt signal can branch off into multiple pathways and each pathway interacts with a different combination of the three domains.
Intending to ameliorate symptoms in those with violent and intractable conditions rather than effect a cure, Burckhardt began operating on patients in December 1888, but both his surgical methods and instruments were crude and the results of the procedure were mixed at best. He operated on six patients in total and, according to his own assessment, two experienced no change, two patients became quieter, one patient experienced epileptic convulsions and died a few days after the operation, and one patient improved. Complications included motor weakness, epilepsy, sensory aphasia and "word deafness". Claiming a success rate of 50 percent, he presented the results at the Berlin Medical Congress and published a report, but the response from his medical peers was hostile and he did no further operations. In 1912, two physicians based in Saint Petersburg, the leading Russian neurologist Vladimir Bekhterev and his younger Estonian colleague, the neurosurgeon Ludvig Puusepp, published a paper reviewing a range of surgical interventions that had been performed on the mentally ill. While generally treating these endeavours favorably, in their consideration of psychosurgery they reserved unremitting scorn for Burckhardt's surgical experiments of 1888 and opined that it was extraordinary that a trained medical doctor could undertake such an unsound procedure.
Part of the Ring of Fire, a region of the world subject to earthquakes and volcanic eruptions, in the interior of Colombia the Andes are the prevailing geographical feature. Most of Colombia's population centers are located in these interior highlands. Beyond the Colombian Massif (in the southwestern departments of Cauca and Nariño), these are divided into three branches known as cordilleras (mountain ranges): the Cordillera Occidental, running adjacent to the Pacific coast and including the city of Cali; the Cordillera Central, running between the Cauca and Magdalena River valleys (to the west and east, respectively) and including the cities of Medellín, Manizales, Pereira, and Armenia; and the Cordillera Oriental, extending northeast to the Guajira Peninsula and including Bogotá, Bucaramanga, and Cúcuta. Peaks in the Cordillera Occidental exceed 4,700 m (15,420 ft), and in the Cordillera Central and Cordillera Oriental they reach 5,000 m (16,404 ft). At 2,600 m (8,530 ft), Bogotá is the highest city of its size in the world. The main rivers of Colombia are Magdalena, Cauca, Guaviare, Atrato, Meta, Putumayo and Caquetá. Colombia has four main drainage systems: the Pacific drain, the Caribbean drain, the Orinoco Basin and the Amazon Basin. The Orinoco and Amazon Rivers mark limits with Colombia to Venezuela and Peru respectively.
Sources: en.wikipedia.org
== Medical application == S. helianthus shows a variety of promising applications in the medical field due to its toxin-producing capability. ShK-186, a peptide inhibitor, is a toxin that has been previously implemented in clinical trials for its potential treatment of autoimmune diseases. It has been further developed into an “investigational drug”, known as Dalazatide, in which it targets the disease-causing cells corresponding to ailments including type 1 diabetes, lupus erythematosus and multiple sclerosis. The aforementioned cytolysins, St I and St II, have also shown pharmacological potential in studies with guinea pig models, with direct implications on neural and cardiac activity. Due to its capability of protease inhibition, ShPI-1 is another toxin with medical potential. This toxin is a “non-specific inhibitor” and provides a variant with “increased biomedical potential” for its inhibition properties. Though many of these toxins require further research, S. helianthus serves great potential in biomedical applications for toxin production.
=== Glutaminolysis and transamination === Aside from the citric acid cycle, α-ketoglutarate is made by glutaminolysis in which the enzyme glutaminase removes the amino group from glutamine to form glutamate which is converted to α-ketoglutarate by any one of three enzymes, glutamate dehydrogenase, alanine transaminase, or aspartate transaminase (see The glutaminolytic pathways). It is also made through the action of pyridoxal phosphate-dependent enzymes (alanine transaminase) in which glutamate is converted to α-Ketoglutarate by "donating" its −NH2 to other compounds (see transamination). These reactions are reversible. In the reverse direction of these reactions, α-ketoglutarate contributes to the production of amino acids such as glutamine, proline, arginine, and lysine as well as the lowering of cellular carbon and nitrogen (i.e., N) levels; this prevents excessive levels of these two potentially toxic elements from accumulating in cells and tissues. The neurotoxin, ammonia (i.e., NH3), is also prevented from accumulating in tissues. In this metabolic pathway the −NH2 group on an amino acid is transferred to α-ketoglutarate; this forms the α-keto acid of the original amino acid and the amine-containing product of α-ketoglutarate, glutamate. The cellular glutamate passes into the circulation and is taken up by the liver where it delivers its acquired −NH2 group to the urea cycle. In effect, the latter pathway removes excess ammonia from the body in the form of urinary urea.
Tea was consumed as a recreational and social beverage during the Tang dynasty, and Chinese tea culture-inspired ceremonial drinking spread to other Sinospheric countries such as Japan (where it is known as chado), Korea (known as darye) and Vietnam (typically as part of a wedding ritual). Tea drinking also spread into Inner Asia and South Asia via the Silk Road and the Tea Horse Road, particularly during the expansion of the Mongols, for whom the salted milk tea (süütei tsai) has remained part of the staple diet. Outside of the Far East, Portuguese priests and merchants introduced tea drinking to Europe during the 16th century. During the 17th century, drinking tea became fashionable in Western Europe as part of the rise of Chinoiserie influence, especially among the British, who had such a high import demand of tea that they later started to cultivate tea on a large scale in colonial India and Ceylon, where tea had previously been used only as a herbal medicine.
== Awards and honors == Fulbright fellowship for research in pediatric hematology Honorary Doctorate of Science from William Woods College (1972) Honorary service award from the Ohio State University Home Economics Alumni Association Honorary member of the Turkish Society of Hematology Selected as a "Woman of Achievement" by the Group Action Council of Metropolitan St. Louis (1947)
Sources: en.wikipedia.org
In his introduction, he praised Chomsky as "a very vocal and important voice in the wilderness of intellectual life in America" and said that he was "delighted to welcome a person who I think we're all very proud of". Sanders hosted and produced a public-access television program, Bernie Speaks with the Community, from 1986 to 1988. He collaborated with 30 Vermont musicians to record a folk album, We Shall Overcome, in 1987. That same year, US News & World Report ranked Sanders one of America's best mayors. As of 2013, Burlington was regarded as one of the most livable cities in the United States. During a trip to the Soviet Union in 1988, Sanders interviewed the mayor of Burlington's sister city Yaroslavl about housing and health care issues in the two cities. When Sanders left office in 1989, Bouricius, a member of the Burlington city council, said that Sanders had "changed the entire nature of politics in Burlington and also in the state of Vermont".
=== Critical response === On Rotten Tomatoes, the first season has an approval rating of 89% based on 38 reviews, with an average rating of 7.61/10. The website's critical consensus reads: "A stellar series perfect for anyone looking for a little hope, Stargirl is delightful fun the whole family can enjoy". On Metacritic it has a weighted average score of 68 out of 100 based on 8 reviews, indicating "generally favorable reviews". Brian Lowry of CNN described the series as "hardly seeks to reinvent the wheel, or even expand the mold. Still, its mix of solid characters, clever writing and youthful exuberance casts a brighter light than most". Daniel Fienberg of The Hollywood Reporter gave a review, calling it "derivative, but should fill the superhero-origin-story-shaped hole in your heart" and wrote: "The result is that a show that is frequently derivative to the point of distraction might actually fill a need for viewers able to concentrate on its occasional charms until better superhero shows return". On Rotten Tomatoes, the second season holds an approval rating of 100% based on 5 reviews, with an average rating of 8.2/10.
=== 2010s === In January 2010, Sonic announced that they would begin switching to battery cage-free eggs, gestation crate-free pork, and chickens killed using controlled-atmosphere stunning methods instead of traditional shackling and electrical stunning. The company has subsequently backtracked on these commitments and now faces public criticism. Sonic reformulated its soft-serve ice cream to meet the FDA standards of identity that define what constitutes real ice cream and introduced Real Ice Cream on May 17, 2010. Several new hot dog items were also introduced in June 2010 and February 2011. Craig Miller was hired as chief information officer in January 2012. In June 2010, Danielle Vona was hired as chief marketing officer. In late 2010, Sonic announced the end of its 17-year relationship with advertising agency Barkley. A group of specialized agencies was selected to represent the company, and in early 2011, San Francisco-based Goodby Silverstein and Partners was named as the new creative agency for the company. In 2017, Sonic announced it would add seven new stores in Hawaii in the near future. However, its first location in the state would not open unilt May 2026 with a single location in Kapolei. In September 2017, Sonic opened its first location in Alaska in Wasilla, and a year later it opened its second Alaska location in Fairbanks. On September 25, 2018, Atlanta-based Inspire Brands, owner of Arby's and Buffalo Wild Wings, announced that it would acquire Sonic for $2.3 billion. The acquisition was completed on December 7, 2018. While he was with the St.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.